At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4599 Weight Loss Drugs
Trading 12-17 15:14:13 EST
1,454.83
-16.03
-1.09%
High1,477.26Low1,449.93Vol55.17M
Open1,471.51D1 Closing1,470.86Amplitude1.86%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O4.23BT/O Rate--Tradable Shares0.00
P/B9.709976ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Correction to Lilly Drug Trial Article on Dec. 11
Dow Jones  ·  02:35
Correction to Lilly Drug Trial Article on Dec. 11
FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit
Benzinga_recent_news  ·  00:42
FDA Approves Brain Tumor Warning For Pfizer's Depo-Provera Amid Lawsuit
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
Benzinga_recent_news  ·  12-17 23:14
Pfizer, Merck Are Boring Again — And That's Exactly Why 2026 Investors Are Circling Back
BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
Reuters  ·  12-17 22:38
BRIEF-Structure Therapeutics Starts Phase 1 Study Of Oral Amylin Agonist ACCG‑2671
Deutsche Bank Adjusts Price Target on Eli Lilly to $1,200 From $1,000, Maintains Buy Rating
MT Newswires Live  ·  12-17 22:15
Deutsche Bank Adjusts Price Target on Eli Lilly to $1,200 From $1,000, Maintains Buy Rating
BRIEF-Medi&Gene Announces Catalyze Agreement With Lilly
Reuters  ·  12-17 21:57
BRIEF-Medi&Gene Announces Catalyze Agreement With Lilly
Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
Reuters  ·  12-17 21:30
Structure Therapeutics Launches Phase 1 Trial of Oral Amylin Agonist ACCG-2671 for Obesity
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity
THOMSON REUTERS  ·  12-17 21:30
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist Accg-2671 for the Treatment of Obesity
Medi&Gene Announces Catalyze Agreement With Lilly to Advance Next-Generation Obesity Therapeutics
THOMSON REUTERS  ·  12-17 21:01
Medi&Gene Announces Catalyze Agreement With Lilly to Advance Next-Generation Obesity Therapeutics
ChatGPT Makes $2,000 Per Month Dividend Portfolio For A 58-Year-Old Nearing Retirement: Top 6 Stocks
Benzinga_recent_news  ·  12-17 21:00
ChatGPT Makes $2,000 Per Month Dividend Portfolio For A 58-Year-Old Nearing Retirement: Top 6 Stocks
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire  ·  12-17 21:00
Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference
Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study
Dow Jones  ·  12-17 20:38
Merck, Pfizer, Astellas Drug Combo Succeeds in 2nd Phase 3 Bladder Cancer Study
BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Reuters  ·  12-17 19:45
BRIEF-Pfizer Says Phase 3 EV-304 Clinical Trial Meets Primary Endpoint
Pfizer: Phase 3 EV-304 Trial Showed Clinically Meaningful & Statistically Significant Improvements in Event-Free Survival, & Overall Survival
THOMSON REUTERS  ·  12-17 19:45
Pfizer: Phase 3 EV-304 Trial Showed Clinically Meaningful & Statistically Significant Improvements in Event-Free Survival, & Overall Survival
Pfizer: Safety Profile for Padcev Plus Pembrolizumab Was Consistent With Known Profile of Treatment Regimen
THOMSON REUTERS  ·  12-17 19:45
Pfizer: Safety Profile for Padcev Plus Pembrolizumab Was Consistent With Known Profile of Treatment Regimen
Pfizer: Pathologic Complete Response Rate for Neoadjuvant Padcev Plus Pembrolizumab VS Neoadjuvant Chemotherapy Was Met
THOMSON REUTERS  ·  12-17 19:45
Pfizer: Pathologic Complete Response Rate for Neoadjuvant Padcev Plus Pembrolizumab VS Neoadjuvant Chemotherapy Was Met
Pfizer: Padcev Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
THOMSON REUTERS  ·  12-17 19:45
Pfizer: Padcev Plus Keytruda Significantly Improves Survival for Patients With Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Pfizer Inc. Publishes Transcript of Analyst and Investor Call Reviewing Full-Year 2026 Financial Guidance
Reuters  ·  12-17 11:26
Pfizer Inc. Publishes Transcript of Analyst and Investor Call Reviewing Full-Year 2026 Financial Guidance
Tilray Brands, Pfizer, Netflix, Lennar Corp. And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Benzinga_recent_news  ·  12-17 09:09
Tilray Brands, Pfizer, Netflix, Lennar Corp. And Tesla: Why These 5 Stocks Are On Investors' Radars Today
Health Care Down After Pfizer Warning -- Health Care Roundup
Dow Jones  ·  12-17 06:15
Health Care Down After Pfizer Warning -- Health Care Roundup

Introduction

Company Name.
BK4599
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--